These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
184 related articles for article (PubMed ID: 37095347)
61. Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2. Nguyen KG; Mantooth SM; Vrabel MR; Zaharoff DA Front Immunol; 2022; 13():858904. PubMed ID: 35592324 [TBL] [Abstract][Full Text] [Related]
62. Nanoemulsions and nanocapsules as carriers for the development of intranasal mRNA vaccines. Borrajo ML; Lou G; Anthiya S; Lapuhs P; Álvarez DM; Tobío A; Loza MI; Vidal A; Alonso MJ Drug Deliv Transl Res; 2024 Aug; 14(8):2046-2061. PubMed ID: 38811465 [TBL] [Abstract][Full Text] [Related]
63. Immunogenicity and safety of heterologous booster with protein-based COVID-19 vaccine (NVX-CoV2373) in healthy adults: A comparative analysis with mRNA vaccines. Sheng WH; Lin PH; Cheng YC; Wu YY; Hsieh MJ; Yang HC; Chang SY; Chang SC J Formos Med Assoc; 2024 Mar; 123(3):340-346. PubMed ID: 37996322 [TBL] [Abstract][Full Text] [Related]
64. A Single Dose SARS-CoV-2 Replicon RNA Vaccine Induces Cellular and Humoral Immune Responses in Simian Immunodeficiency Virus Infected and Uninfected Pigtail Macaques. O'Connor MA; Erasmus JH; Randall S; Archer J; Lewis TB; Brown B; Fredericks M; Groenier S; Iwayama N; Ahrens C; Garrison W; Wangari S; Guerriero KA; Fuller DH Front Immunol; 2021; 12():800723. PubMed ID: 34992610 [TBL] [Abstract][Full Text] [Related]
65. An inoculation site-retained mRNA vaccine induces robust immune responses against SARS-CoV-2 variants. Huang L; Zhao F; He M; Fang Y; Ma X; Lu S; Li E; Xiao H; Zhu H; Wang X; Tang S; Yu B; Wang J; Zhao D; Wang C; Li H; Gao Y; Peng X; Shen H J Control Release; 2024 Feb; 366():479-493. PubMed ID: 38184234 [TBL] [Abstract][Full Text] [Related]
66. A Methyltransferase-Defective Vesicular Stomatitis Virus-Based SARS-CoV-2 Vaccine Candidate Provides Complete Protection against SARS-CoV-2 Infection in Hamsters. Lu M; Zhang Y; Dravid P; Li A; Zeng C; Kc M; Trivedi S; Sharma H; Chaiwatpongsakorn S; Zani A; Kenney A; Cai C; Ye C; Liang X; Qiu J; Martinez-Sobrido L; Yount JS; Boyaka PN; Liu SL; Peeples ME; Kapoor A; Li J J Virol; 2021 Sep; 95(20):e0059221. PubMed ID: 34379509 [TBL] [Abstract][Full Text] [Related]
67. Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose. Mwimanzi F; Lapointe HR; Cheung PK; Sang Y; Yaseen F; Umviligihozo G; Kalikawe R; Datwani S; Omondi FH; Burns L; Young L; Leung V; Agafitei O; Ennis S; Dong W; Basra S; Lim LY; Ng K; Pantophlet R; Brumme CJ; Montaner JSG; Prystajecky N; Lowe CF; DeMarco ML; Holmes DT; Simons J; Niikura M; Romney MG; Brumme ZL; Brockman MA J Infect Dis; 2022 Sep; 226(6):983-994. PubMed ID: 35543278 [TBL] [Abstract][Full Text] [Related]
68. Nucleic acid-based vaccine platforms against the coronavirus disease 19 (COVID-19). Baghban R; Ghasemian A; Mahmoodi S Arch Microbiol; 2023 Mar; 205(4):150. PubMed ID: 36995507 [TBL] [Abstract][Full Text] [Related]
69. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccines for Preventing Coronavirus Disease 2019 Hospitalizations in the United States. Tenforde MW; Patel MM; Ginde AA; Douin DJ; Talbot HK; Casey JD; Mohr NM; Zepeski A; Gaglani M; McNeal T; Ghamande S; Shapiro NI; Gibbs KW; Files DC; Hager DN; Shehu A; Prekker ME; Erickson HL; Exline MC; Gong MN; Mohamed A; Henning DJ; Steingrub JS; Peltan ID; Brown SM; Martin ET; Monto AS; Khan A; Hough CL; Busse LW; Ten Lohuis CC; Duggal A; Wilson JG; Gordon AJ; Qadir N; Chang SY; Mallow C; Gershengorn HB; Babcock HM; Kwon JH; Halasa N; Chappell JD; Lauring AS; Grijalva CG; Rice TW; Jones ID; Stubblefield WB; Baughman A; Womack KN; Lindsell CJ; Hart KW; Zhu Y; Olson SM; Stephenson M; Schrag SJ; Kobayashi M; Verani JR; Self WH; Clin Infect Dis; 2022 May; 74(9):1515-1524. PubMed ID: 34358310 [TBL] [Abstract][Full Text] [Related]
70. A PEG-lipid-free COVID-19 mRNA vaccine triggers robust immune responses in mice. Li M; Huang Y; Wu J; Li S; Mei M; Chen H; Wang N; Wu W; Zhou B; Tan X; Li B Mater Horiz; 2023 Feb; 10(2):466-472. PubMed ID: 36468425 [TBL] [Abstract][Full Text] [Related]
71. Perspectives and Prospects on mRNA Vaccine Development for COVID-19. Jin L; Han Z; Zhao P; Sun K Curr Med Chem; 2022; 29(23):3991-3996. PubMed ID: 35170403 [TBL] [Abstract][Full Text] [Related]
72. COVID-19 vaccine mRNA-1273 elicits a protective immune profile in mice that is not associated with vaccine-enhanced disease upon SARS-CoV-2 challenge. DiPiazza AT; Leist SR; Abiona OM; Moliva JI; Werner A; Minai M; Nagata BM; Bock KW; Phung E; Schäfer A; Dinnon KH; Chang LA; Loomis RJ; Boyoglu-Barnum S; Alvarado GS; Sullivan NJ; Edwards DK; Morabito KM; Mascola JR; Carfi A; Corbett KS; Moore IN; Baric RS; Graham BS; Ruckwardt TJ Immunity; 2021 Aug; 54(8):1869-1882.e6. PubMed ID: 34270939 [TBL] [Abstract][Full Text] [Related]
73. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination. Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P Front Immunol; 2022; 13():816389. PubMed ID: 35464418 [TBL] [Abstract][Full Text] [Related]
74. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose. Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I Front Immunol; 2023; 14():1099246. PubMed ID: 36756112 [TBL] [Abstract][Full Text] [Related]
75. Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines. Boley PA; Lee CM; Schrock J; Yadav KK; Patil V; Suresh R; Lu S; Feng MM; Hanson J; Channappanavar R; Kenney SP; Renukaradhya GJ J Nanobiotechnology; 2023 Feb; 21(1):60. PubMed ID: 36814238 [TBL] [Abstract][Full Text] [Related]
76. The Impact of Prior Infection and Age on Antibody Persistence After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine. Fraley E; LeMaster C; Khanal S; Banerjee D; Pastinen T; Grundberg E; Selvarangan R; Bradley T Clin Infect Dis; 2022 Aug; 75(1):e902-e904. PubMed ID: 34551091 [TBL] [Abstract][Full Text] [Related]
77. Poor Antibody Response to BioNTech/Pfizer Coronavirus Disease 2019 Vaccination in Severe Acute Respiratory Syndrome Coronavirus 2-Naive Residents of Nursing Homes. Pannus P; Neven KY; De Craeye S; Heyndrickx L; Vande Kerckhove S; Georges D; Michiels J; Francotte A; Van Den Bulcke M; Zrein M; Van Gucht S; Schmickler MN; Verbrugghe M; Matagne A; Thomas I; Dierick K; Weiner JA; Ackerman ME; Goriely S; Goossens ME; Ariën KK; Desombere I; Marchant A Clin Infect Dis; 2022 Aug; 75(1):e695-e704. PubMed ID: 34864935 [TBL] [Abstract][Full Text] [Related]
78. Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2. Stewart-Jones GBE; Elbashir SM; Wu K; Lee D; Renzi I; Ying B; Koch M; Sein CE; Choi A; Whitener B; Garcia-Dominguez D; Henry C; Woods A; Ma L; Montes Berrueta D; Avena LE; Quinones J; Falcone S; Hsiao CJ; Scheaffer SM; Thackray LB; White P; Diamond MS; Edwards DK; Carfi A Sci Transl Med; 2023 Sep; 15(713):eadf4100. PubMed ID: 37703353 [TBL] [Abstract][Full Text] [Related]
79. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice. González-Domínguez I; Martínez JL; Slamanig S; Lemus N; Liu Y; Lai TY; Carreño JM; Singh G; Singh G; Schotsaert M; Mena I; McCroskery S; Coughlan L; Krammer F; García-Sastre A; Palese P; Sun W Microbiol Spectr; 2022 Jun; 10(3):e0153822. PubMed ID: 35658571 [TBL] [Abstract][Full Text] [Related]
80. Omicron variant Spike-specific antibody binding and Fc activity are preserved in recipients of mRNA or inactivated COVID-19 vaccines. Bartsch YC; Tong X; Kang J; Avendaño MJ; Serrano EF; García-Salum T; Pardo-Roa C; Riquelme A; Cai Y; Renzi I; Stewart-Jones G; Chen B; Medina RA; Alter G Sci Transl Med; 2022 Apr; 14(642):eabn9243. PubMed ID: 35289637 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]